Originally published by our sister publication Infectious Disease Special Edition
The FDA approved the first mRNA respiratory syncytial virus vaccine (mRNA-1345; mRESVIA, Moderna) to protect adults, 60 years of age and older, from lower respiratory tract disease (LRTD) caused by RSV infection.
The FDA’s approval of mRNA-1345 is based on positive data from ConquerRSV, a phase 3 global clinical trial conducted in approximately 37,000 adults 60 years and older in 22 countries. The